trending Market Intelligence /marketintelligence/en/news-insights/trending/PaEOZxk1MBtrDQ8_LSPlyw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA accepts Immunomedics' application for breast cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA accepts Immunomedics' application for breast cancer drug

The U.S. Food and Drug Administration accepted Immunomedics Inc.'s application seeking approval of its medicine sacituzumab govitecan to treat certain patients with breast cancer.

The Morris Plains, N.J.-based company had refiled the biologics license application for accelerated approval of the drug in December after an initial rejection in January. Immunomedics had said the FDA's complete response letter only focused on chemistry, manufacturing and control, and no new clinical or preclinical data was requested.

The company is seeking approval of the medicine to treat patients with triple-negative breast cancer whose disease has spread to other parts of the body and who did not get better after receiving two previous treatments.

Immunomedics said in a Dec. 26 news release that the FDA is expected to make a decision on the application around June 2, 2020.

Sacituzumab govitecan already has the FDA's fast track and breakthrough therapy designations.